VolitionRx Limited Interest Expense, Other
VolitionRx Limited (VNRX) reported Interest Expense, Other of $532.19 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseOther · last filed 2026-03-31
- VolitionRx Limited interest expense, other for the quarter ending 2025-12-31 was $168.37K, a 82.04% increase year-over-year.
- VolitionRx Limited interest expense, other for the quarter ending 2025-09-30 was $143.80K, a 60.75% increase year-over-year.
- VolitionRx Limited interest expense, other for the quarter ending 2025-06-30 was $123.36K, a 51.95% increase year-over-year.
- VolitionRx Limited interest expense, other for the quarter ending 2025-03-31 was $96.67K, a 25.17% increase year-over-year.
- VolitionRx Limited interest expense, other for fiscal 2025 was $532.19K, a 56.36% increase from fiscal 2024.
- VolitionRx Limited interest expense, other for fiscal 2024 was $340.36K, a 53.58% increase from fiscal 2023.
- VolitionRx Limited interest expense, other for fiscal 2023 was $221.62K, a 28.04% increase from fiscal 2022.
- VolitionRx Limited interest expense, other for fiscal 2022 was $173.09K, a 11.09% increase from fiscal 2021.
| Period end | Interest Expense, Other 3 month | Interest Expense, Other 6 month | Interest Expense, Other 9 month | Interest Expense, Other 12 month |
|---|---|---|---|---|
| 2025-12-31 | $168.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $312.17K derived: sum of 2 quarters · filed 2026-03-31 | $435.52K derived: sum of 3 quarters · filed 2026-03-31 | $532.19K 10-K · filed 2026-03-31 |
| 2025-09-30 | $143.80K 10-Q · filed 2025-11-13 | $267.16K derived: sum of 2 quarters · filed 2025-11-13 | $363.82K 10-Q · filed 2025-11-13 | $456.32K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | $123.36K 10-Q · filed 2025-08-14 | $220.03K 10-Q · filed 2025-08-14 | $312.52K derived: sum of 3 quarters · filed 2026-03-31 | $401.97K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | $96.67K 10-Q · filed 2025-05-15 | $189.16K derived: sum of 2 quarters · filed 2026-03-31 | $278.62K derived: sum of 3 quarters · filed 2026-03-31 | $359.80K derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | $92.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $181.95K derived: sum of 2 quarters · filed 2026-03-31 | $263.13K derived: sum of 3 quarters · filed 2026-03-31 | $340.36K 10-K · filed 2026-03-31 |
| 2024-09-30 | $89.46K 10-Q · filed 2025-11-13 | $170.64K derived: sum of 2 quarters · filed 2025-11-13 | $247.87K 10-Q · filed 2025-11-13 | $305.87K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $81.18K 10-Q · filed 2025-08-14 | $158.41K 10-Q · filed 2025-08-14 | $216.41K derived: sum of 3 quarters · filed 2025-08-14 | $270.39K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $77.23K 10-Q · filed 2025-05-15 | $135.23K derived: sum of 2 quarters · filed 2025-05-15 | $189.21K derived: sum of 3 quarters · filed 2025-05-15 | $247.53K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $111.98K derived: sum of 2 quarters · filed 2025-03-31 | $170.30K derived: sum of 3 quarters · filed 2025-03-31 | $221.62K 10-K · filed 2025-03-31 |
| 2023-09-30 | $53.98K 10-Q · filed 2024-11-14 | $112.30K derived: sum of 2 quarters · filed 2024-11-14 | $163.62K 10-Q · filed 2024-11-14 | $220.85K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $58.32K 10-Q · filed 2024-08-14 | $109.64K 10-Q · filed 2024-08-14 | $166.87K derived: sum of 3 quarters · filed 2024-08-14 | $204.57K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $51.32K 10-Q · filed 2024-05-13 | $108.55K derived: sum of 2 quarters · filed 2024-05-13 | $146.25K derived: sum of 3 quarters · filed 2024-05-13 | $183.38K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $57.23K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $94.93K derived: sum of 2 quarters · filed 2024-03-25 | $132.06K derived: sum of 3 quarters · filed 2024-03-25 | $173.09K 10-K · filed 2024-03-25 |
| 2022-09-30 | $37.70K 10-Q · filed 2023-11-14 | $74.83K derived: sum of 2 quarters · filed 2023-11-14 | $115.86K 10-Q · filed 2023-11-14 | $151.03K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $37.13K 10-Q · filed 2023-08-14 | $78.16K 10-Q · filed 2023-08-14 | $113.33K derived: sum of 3 quarters · filed 2023-08-14 | $152.09K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $41.03K 10-Q · filed 2023-05-10 | $76.20K derived: sum of 2 quarters · filed 2023-05-10 | $114.97K derived: sum of 3 quarters · filed 2023-05-10 | $154.65K derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $35.17K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $73.93K derived: sum of 2 quarters · filed 2023-03-15 | $113.62K derived: sum of 3 quarters · filed 2023-03-15 | $155.80K 10-K · filed 2023-03-15 |
| 2021-09-30 | $38.77K 10-Q · filed 2022-11-14 | $78.45K derived: sum of 2 quarters · filed 2022-11-14 | $120.64K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $39.69K 10-Q · filed 2022-08-10 | $81.87K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |